The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Open accessAbstract
BACKGROUND Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. METHODS PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to <60 mL/min per 1·73 m2 and ≥60 mL/min per 1·73 m2) and urine protein excretion at screening (≤1·75 g/day and >1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. FINDINGS Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. INTERPRETATION Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. FUNDING Travere Therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wyatt, R. J., & Julian, B. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1206793 · Cited by 1,222
Levey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
Self-citationHeerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
Self-citationDesign, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Wanner, C., Green, J. B., Hauske, S. J., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac040 · Cited by 110
Research works printed but not linked: 26
- Maisonneuve, 2000, Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study, Am J Kidney Dis, 35, 157, 10.1016/S0272-6386(00)70316-7 · DOI · Paper page
- Reich, 2007, Remission of proteinuria improves prognosis in IgA nephropathy, J Am Soc Nephrol, 18, 3177, 10.1681/ASN.2007050526 · DOI · Paper page
- Rovin, 2021, KDIGO 2021 clinical practice guideline for the management of glomerular diseases, Kidney Int, 100, S1, 10.1016/j.kint.2021.05.021 · DOI · Paper page
- Coppo, 1993, Angiotensin II local hyperreactivity in the progression of IgA nephropathy, Am J Kidney Dis, 21, 593, 10.1016/S0272-6386(12)80031-X · DOI
- De Miguel, 2016, Endothelin-1 and the kidney: new perspectives and recent findings, Curr Opin Nephrol Hypertens, 25, 35, 10.1097/MNH.0000000000000185 · DOI
- Kohan, 2014, Endothelin and endothelin antagonists in chronic kidney disease, Kidney Int, 86, 896, 10.1038/ki.2014.143 · DOI · Paper page
- Komers, 2016, Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease, Am J Physiol Regul Integr Comp Physiol, 310, R877, 10.1152/ajpregu.00425.2015 · DOI
- Smeijer, 2021, Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease, Curr Opin Nephrol Hypertens, 30, 456, 10.1097/MNH.0000000000000716 · DOI
- Trachtman, 2020, Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, treatment of focal segmental glomerulosclerosis, treatment of IgA nephropathy, Drugs Future, 45, 79, 10.1358/dof.2020.45.2.3058863 · doi:10.1358/dof.2020.45.2.3058863
- Dhaun, 2012, Endothelin-1 and the kidney—beyond BP, Br J Pharmacol, 167, 720, 10.1111/j.1476-5381.2012.02070.x · doi:10.1111/j.1476-5381.2012.02070.x
- Dhaun, 2011, Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease, Hypertension, 57, 772, 10.1161/HYPERTENSIONAHA.110.167486 · DOI · Paper page
- de Zeeuw, 2014, The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy, J Am Soc Nephrol, 25, 1083, 10.1681/ASN.2013080830 · DOI · Paper page
- Heerspink, 2019, Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial, Lancet, 393, 1937, 10.1016/S0140-6736(19)30772-X · DOI · Paper page
- Komers, 2017, Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET), Kidney Int Rep, 2, 654, 10.1016/j.ekir.2017.02.019 · DOI
- Komers, 2020, Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis, Kidney Int Rep, 5, 494, 10.1016/j.ekir.2019.12.017 · DOI
- Trachtman, 2018, DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS, J Am Soc Nephrol, 29, 2745, 10.1681/ASN.2018010091 · doi:10.1681/asn.2018010091
- Barratt, 2019, Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial), Kidney Int Rep, 4, 1633, 10.1016/j.ekir.2019.08.007 · DOI
- Barratt, 2023, IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study, Kidney Int Rep, 10.1016/j.ekir.2023.02.1086 · DOI
- Thompson, 2019, Proteinuria reduction as a surrogate end point in trials of IgA nephropathy, Clin J Am Soc Nephrol, 14, 469, 10.2215/CJN.08600718 · DOI · Paper page
- Inker, 2021, Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis, Am J Kidney Dis, 78, 340, 10.1053/j.ajkd.2021.03.007 · DOI
- Lehrke, 2001, Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria, J Am Soc Nephrol, 12, 2321, 10.1681/ASN.V12112321 · DOI
- Nakamura, 1993, Endothelin-1 mRNA expression by peripheral blood monocytes in IgA nephropathy, Lancet, 342, 1147, 10.1016/0140-6736(93)92126-E · doi:10.1016/0140-6736(93)92126-e
- Boels, 2016, Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy, Diabetes, 65, 2429, 10.2337/db15-1413 · DOI
- Benigni, 2021, Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition, Pediatr Nephrol, 36, 763, 10.1007/s00467-020-04518-2 · DOI
- Martínez-Díaz, 2023, Endothelin receptor antagonists in kidney disease, Int J Mol Sci, 24, 10.3390/ijms24043427 · DOI
- Wheeler, 2021, A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy, Kidney Int, 100, 215, 10.1016/j.kint.2021.03.033 · DOI · Paper page
Cited by
Rovin, B. H., Barratt, J., Heerspink, H. J. L., Alpers, C. E., Bieler, S., Chae, D.-W., Diva, U. A., Floege, J., Gesualdo, L., Inrig, J. K., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02302-4 · Cited by 307
Self-citationThe pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
Self-citationRovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarch, H., & Floege, J. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.004 · Cited by 206
Self-citationAtrasentan in Patients with IgA Nephropathy
Heerspink, H. J. L., Jardine, M., Kohan, D. E., Lafayette, R. A., Levin, A., Liew, A., Zhang, H., Lodha, A., Gray, T., Wang, Y., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2409415 · Cited by 142
Self-citationApperloo, E. M., Gorriz, J. L., Soler, M. J., Cigarrán Guldris, S., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Waanders, F., Laverman, G. D., van der Aart-van der Beek, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03327-6 · Cited by 120
Self-citation
Metadata
- Authors
- Heerspink, H. J. L., Radhakrishnan, J., Alpers, C. E., Barratt, J., Bieler, S., Diva, U., Inrig, J., Komers, R., Mercer, A., Noronha, I. L., Rheault, M. N., Rote, W., Rovin, B., Trachtman, H., Trimarchi, H., Wong, M. G., Perkovic, V., Alarmartine, E., Barratt, J., Chae, D. W., Del Vecchio, L., Floege, J., Hwang, S.-J., Jelakovic, B., Maes, B., Malecki, R., Miglinas, M., Nolasco, F. E. B., Praga, M., Rabindranath, K., Rosenberg, M., Rovin, B., Tang, S. C. W., Tesar, V., Wong, M. G., Bose, B., Gangadharan, M., McDonald, S., Peh, C., Jahan, S., Yeap, C., Clayton, P., Irish, G., Thyagarajan, N., Hollett, P., Krishnasamy, R., Carroll, R., Jesudason, S., Crail, S., Coates, T., Waugh, J., Noble, E., Mahadevan, K., Campbell, V., Salehi, T., Lim, W., Boudville, N., Chakera, A., Chan, D., Krishnan, A., Eqbal, Y., Gillies, A., Vilayur, E., Maung Myint, T. M., Gray, N., Waugh, J., Noble, E., Cheetham, M., Eqbal, Y., Hollett, P., Krishnasamy, R., Mahadevan, K., Campbell, V., Pollock, C., Cooper, B., Mather, A., Roxburgh, S., Shen, Y., Stangenberg, S., Siriwardana, A., O'Lone, E., Wan, S., Neuen, B., Tsun Kit Ha, J., Kim, D., Heath, L., Jain, A., Phua, E., Li, Y., Gallagher, M., Jardine, M., Ritchie, A., Razavian, M., Foote, C., Wyndham, R., Sen, S., Endre, Z., Erlich, J., Fernando, M., Yong, K., Luxton, G., Kotwal, S., Roger, S., Wijeratne, V., Packham, D., Fraser, I., Vandewiele, B., Laute, M., Lemahieu, W., Jamar, S., Ombelet, S., Meeus, G., Decupere, M., Schockaert, O., Doubel, P., Viaene, L., Radermacher, L., Masset, C., Moonen, M., Firre, E., Milicevic, M., Warling, X., Vanacker, A., Malfait, T., Durlen, I., Horvatic, I., Savuk, A., Gellineo, L., Karanovic, S., Dika, Z., Plavljanic, D., Mikacic, I., Trajbar Kentric, D., Barisic, D., Stankovic, M., Majstorovic Barac, K., Kruljac, I., Pavlovic, D., Drinkovic, M., Prkacin, I., Barbic, J., Sitas, Z., Vujcic, D., Rychlik, I., Benesova, A., Drinovska, K., Kratka, K., Maixnerova, D., Ilmoja, M., Unt, K., Lilienthal, K., Auerbach, A., Leis, L., Piel, J., Adoberg, A., Kolvald, K., Veermae, K., Telling, K., Seppet, E., Uhlinova, J., Zaoui, P., Carron, P.-L., Masson, I., Dinic, M., Thibaudin, D., Broyet, C., Maillard, N., Mohey, H., Mariat, C., Claisse, G., Alamartine, E., Dussol, B., Burtey, S., Chiche-Jourde, N., Serre, J.-E., Jeantet, G., Chenine, L., Blanchard, A., Roueff, S., Thervet, E., Fouassier, D., Buffet, A., Livrozet, M., Gaisset, R., Karras, A., Heng, A.-E., Garrouste, C., Philipponnet, C., Nicolo, C., Atenza, A., Lanaret, C., Greze, C., Mayet, V., Dumond, C., Delmas, Y., Combe, C., Rigothier, C., Burguet, L., Labat, A., Mucha, S., de Précigout, V., Weinreich, T., Reichel, H., Draganova, D., Wolf, L., Hohenstein, B., Heinrichs, S., Kulka, S., Sat, S., Weiland, L., Krueger, T., Wolf, G., Kettner, C., Schlosser, M., Herfurth, J. K., Koch, A., Busch, M., Werth, S. C., Nitschke, M., Cakiroglu, F., Sarnow, F., Schulz, L., Weiner, S., Wirtz, N., Koester, E., Moeller, M., Stamellou, E., Sanden, S., Schmidt-Guertler, H., Bernhardt, W., Patecki, M., Schlieper, G., Schulte, K., Girardet, A., Kunzendorf, U., Kwan, L. P. Y., Mok, M. M. Y., Chan, G. C. W., Ma, M., Lie, D. N. W., Chan, A. T. P., Szeto, C. C., Ng, K. C. J., Cheung, S. F., Yue, T. T. A., Fung, K. S. S., Tang, H., Yim, K. F., Law, W. P., Wong, Y. H., Lam, C. K. D., Wong, S. H. S., Marcantoni, C., Aliotta, R., Deodato, F., Patella, G., Comi, N., Vita, C., Carullo, N., Bolignano, D., Musolino, M., Trillini, M., Perico, N., Remuzzi, G., Daina, E., Biancone, L., Colla, L., Burdese, M., Cogno, C., Boaglio, E., Abbasciano, I., Zizzi, C. F., Randone, P., Napodano, P., Ricchiuto, A., Cassia, M., Accarino, S., Cozzolino, M., Baccaro, R., Costanzi, S., Di Maio, F., Arena, M., Urciuolo, F., Vigano, S., Cavalli, A., Limardo, M., Bordoli, M., Ponti, S., Longhi, S., Solazzo, A., Giaroni, F., Donati, G., Torreggiani, M., Catucci, D., Colucci, M., Esposito, V., Esposito, C., Gesualdo, L., Capaccio, F., Diletta Stea, E., Sivo, C., Annese, F., Papadia, F., Messa, P., Belingheri, M., Passerini, P., Malvica, S., Vickiene, A., Zakauskiene, U., Asakiene, E., Bumblyte', I. A., Stankuviene, A., Santockiene, L., Hayat, A., Williams, A., Sizeland, P., Tan, E., Waters, G., Chan, L. W., Henderson, A., Turnbull, A., McNally, A., Reynolds, A., Pilmore, H., Dittmer, I., Manley, P., Stallworthy, E., Goh, T., Semple, D., Collins, M., Curry, E., Ahmed, J., Nguyen, T., Winiarska, A., Zbrzezniak, J., Stompor, T., Krajewska, M., Augustyniak-Bartosik, H., Zielinska, D., Jander, A., Stanczyk, M., Tkaczyk, M., Miarka, P., Aksamit, D., Jaskowski, P., Sulowicz, W., Cieniawski, D., Gontarek-Kacprzak, J., Felicjanczuk, E., Kwella, N., Kwella, B., Satora, E., Fernandes, J. C., Gomes, A. M., Reis, M., Lopes, D., Almeida, C., Sá, H., Figueiredo, A. C., Pardinhas, C., Almeida, E., Raimundo, M., Cortesão Costa, A., Falcao Goncalves, L. P., Fernandes, S., Silva, S., Teixeira, C., Fernandes, A., Nolasco, F., Alves, P., Gois, M., Fonseca, N., Messias, A., Menezes, M., Cardoso, F., Sousa, H., Marques, J., Barata, R., Lopes, J. A., Jorge, S., Gameiro, J., de Almeida Agapito Fonseca, J. N., Goncalves, S., Farinha, A., Valerio Santos, P., Natario, A., de Jesus Barreto, J. C., Abrantes, C., Quadrado Soares, E. S., Soares Felgueiras, J. D. S., Cunha, L., Parreira, L., Furtado, T., Vaz, A., Oh, K.-H., Lee, H., Joong Kim, S., Jeong, J. C., Hoon Kim, Y., Kim, Y., Park, H. C., Choi, H. Y., Wook Kim, H., Lee, M. H., Yoon, S., Lee, K.-B., Hyun, Y., Yoo, T.-H., Han, S. H., Park, J. T., Kim, S., Song, Y. R., Kim, J.-K., Lee, H.-S., Joo, N., Lee, J., Ryoun Jang, H., Jeon, J., Chung, W., Lee, H., Chang, J. H., Chun, K. Y., Jung, J. Y., Ro, H., Kim, A., Jo, S.-K., Yang, J., Kim, M.-G., Oh, S., Martinez Villanueva, C., Gimeno, A. V., Andres Useche Bonilla, G., Tamarit, E., Galan Serrano, A., Verde Moreno, E., Fernandez, J. L., Goicoechea Diezhandino, M. A., Verdalles Guzman, U., de Jose, A. P., Ortiz Arduan, A., Pérez Gómez, M. V., Martín Cleary, C., Prado, R. F., Goma, E., Ballarin, J., Encarnacion, M. D., Da Silva Santos, I., Marco Rusinol, H., Furlano, M., Arias, C., Barrios, C., Garcia, E. R., Sierra Ochoa, A., Vizcaino Castillo, B., Pantoja Perez, J., Gonzalez Moya, M., Sargsyan, M., Calatayud Aristoy, E., Bernabeu, A. A., Perez Lluna, L., Malek Marin, T., Antonia Munar Vila, M., Bobadilla Rico, I. M., Allende Burgos, N., Gutierrez Martinez, E., Gutierrez Solis, E., Sevillano, A., Merida Herrero, E., Miquel Blasco Pelicano, J., Rodas Marin, L. M., Quintana, L. F., Antonieta Azancot Rivero, M., Ramos Terrades, N., Garcia Carro, C., Agraz Pamplona, I., Salgueira Lazo, M., de la Prada Alvarez, F., Alonso Garcia, F., Adrian Aguilera Morales, W., Virxinia Pol Heres, S., Forcen, A., Parra Moncasi, E., Medrano Villarroya, C., Soria Villen, A., Gracia Garcia, O., Velo Plaza, M., Sánchez de la Nieta, M. D., Calvo Arevalo, M., Moreno, A., Cigarran Guldris, S., de Vicente, M. P., Munar Vila, M. A., Bobadilla Rico, I. M., Allende Burgos, N., Hsu, B.-G., Wang, C.-H., Chen, C.-H., Yu, T.-M., Wu, M.-J., Tsai, S.-F., Hsu, C.-T., Chiu, H.-F., Chou, K.-J., Fang, H.-C., Lee, P.-T., Chen, H.-Y., Chen, C.-L., Huang, C.-W., Ou, S.-H., Ho, T.-Y., Hsu, C.-Y., Chang, M.-S., Chiu, Y.-L., Peng, Y.-S., Shu, K.-H., Pan, S.-Y., Hsu, S.-P., Yang, J.-Y., Pai, M.-F., Tseng, P.-Y., Wu, H.-Y., Tsai, W.-C., Tung, K.-T., Chen, H.-Y., Chen, H.-C., Kuo, M.-C., Hwang, D.-Y., Chiu, Y.-W., Hung, C.-C., Kuo, H.-T., Tsai, J.-C., McCafferty, K., Forbes, S., Dasgupta, I., Thomas, M., Mahdi, A., Ajayi, B., Chowdhury, P., Kasimatis, T., Moutzouris, D., Dudreuilh, C., Pruthi, R., Mansfield, N., Doctor, G., Shah, S., Kon, S., Smith, P., Hamilton, P., Kanigicherla, D., Ibrahim Ragy, O. S., Alchi, B., Flossmann, O., Ghalli, F., Lawman, S., Sinha, S., Chrysochou, C., Chukwu, C., Maire De Bhailis, A., Al Chalabi, S., Hudson, A., Gopu, A., Wickens, O., Storrar, J., Wahba, M., Lorde, N., Rony, M., Griffin, S., Latif, F., Ali, M., DaSilva, L., Ayling-Smith, J., Mahdi, E., Willcocks, L., Jones, R., Cheung, C. K., Selvaskandan, H., Pugh, D., Sayer, M., Dhaun, N., Chapman, F., Mark, P., Geddes, C., McQuarrie, E., Patel, R., Solomon, L., Ponnusamy, A., Morris, A., Okoh, P., Floyd, L., Dhaygude, A., Leung, J., Goldsmith, C., Pandya, B., Tez, D., Mikhail, A., Brown, K., Bucknall, T., Lambie, M., Comunale, R., Brandon, D., Martinez, S., Hall, A., Henderson, A., Fearday, A., Douthit, N., Snow, B., Silva, A., Sly, C., Keller, C., Davidson, R., Meng, J., Haws, R., Kattamanchi, S., Mojarrab, J., Pillai, U., Lafayette, R., O'Shaughnessy, M., Kamal, F., Mehta, K., Baker, B., Ruiz, M., Jyothinagaram, P., Peri, U., Paxton, W., Tumlin, J., McGreal, K., McCarthy, E., Kimber, C., Gautam, A., Khalil, K., Nguyen, V., Nguyen, V., Minasian, R., Arfaania, D., Daneshvari, S., Zakari, M., Patrikyan, A., Afsari, R., Ayvazyan, C., Fakih, F., Lagatta, M., Fakih, F., Rodriguez, A., Avella, J. E. M., Patak, R., Kadakia, J., Radhakrishnan, J., Appel, G., Ahn, W., Nelson, B., Medina, A., Ahmad, S., Peleg, Y., Clement, N., Chiu, I., Hendren, E., Bomback, A., Canetta, P., Spinowitz, B., Charytan, C., Parikh, N., Kuo, S., Raichoudhury, R., Dobre, M., Negrea, L., Padiyar, A., Jittirat, A., Pradhan, N., Dhelaria, R., Balamuthusamy, S., Madhrira, M., Powell, T., Lifland, H., Bailey, A., Ford Sightler, S. A., Suthar, M. P., Green, H., Parikh, S., Ayoub, I., Almaani, S., Contreras, G., Fornoni, A., Drexler, Y., Geara, A., Sheridan, B., Coppock, G., Hogan, J., Gonzalez, C., Bhadra, S., Chowdhury, P., Kyaw, K., Tan, M., Raakesh, L., Mendoza, E., Viramontes, V., Chaudhry, A., Carbonell, J., Gadh, R., Fernandez, V., Kassem, M., Jacob, R., Wilder, K., Newsome, B., Klamm, K., Suyumova, I., Kooienga, L. A., Janko, C., Rizk, D., Julian, B., Caster, D., Perez, E., Garg, G., Gowda, N., Udani, S., Mandayam, S., Workeneh, B., Comunale, R., Brandon, D., Pillai, U., Assefi, A., Greco, B., Germain, M., Patel, J., Quinn, S., Sullivan, J., Glaze, J., Madonia, P., McMahon, K., Giles, H., Adler, S., & Dai, T.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 401
- Issue
- 10388
- Pages
- 1584-1594
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4362453755
- Cited by
- 224
- References
- 4
- FWCI
- 36.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00569-x
- The paper
- Heerspink, H. J. L., Radhakrishnan, J., Alpers, C. E., Barratt, J., Bieler, S., Diva, U., Inrig, J., Komers, R., Mercer, A., Noronha, I. L., Rheault, M. N., Rote, W., Rovin, B., Trachtman, H., Trimarchi, H., Wong, M. G., Perkovic, V., Alarmartine, E., Barratt, J., . . . Dai, T. (2023). Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)00569-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.